How your uterine cancer stage and genetic profile guides treatment

Your uterine cancer treatment is determined by one foundational step: surgical staging, and everything that follows flows from what that surgery reveals.

Unlike some cancers staged through imaging alone, uterine cancer staging is often confirmed in the operating room. Staging is based on the FIGO (International Federation of Gynecology and Obstetrics) system, which classifies uterine cancer into four stages depending on how far the cancer has spread. Imaging tests and pathology results help determine your stage and guide your treatment plan. This means your oncology team often won’t have a definitive stage until after your hysterectomy is complete. That’s an important distinction to understand before your treatment conversations begin.

Each stage reflects how far the disease has extended beyond its origin point, and that information directly shapes the therapy your care team recommends. The FIGO system is clinically powerful because it uses cumulative logic: as the stage advances, treatment typically layers additional modalities on top of surgery. A stage I diagnosis typically requires surgery alone, while a stage III or IV diagnosis often calls for a combination of surgery, radiation, and chemotherapy.

Staging is also the primary tool oncologists use to predict outcomes and select therapy with precision. It reveals where the cancer is and how aggressively it needs to be treated. Your genetic and biomarker profile, including factors like mismatch repair status, helps doctors better classify your cancer, predict your prognosis, and personalize your treatment plan. The sections that follow break down exactly what that plan looks like, starting with the most common diagnosis: Stage I.

Stage I: focus on surgical cure and risk mitigation

For most patients diagnosed with stage I uterine cancer, surgery is the primary, and often the only, treatment needed to achieve a cure.

For most patients with Stage I uterine cancer, surgery to remove the uterus, fallopian tubes, and ovaries (total hysterectomy with bilateral salpingo-oophorectomy) is standard treatment, though your doctor may recommend variations based on your age, overall health, cancer grade, and whether you wish to preserve fertility. Today, many surgical teams favor minimally invasive techniques, robotic or laparoscopic surgery, over open abdominal procedures. In practice, these approaches typically mean less blood loss, shorter hospital stays, and faster recovery without compromising outcomes.

For high-risk stage I cases, surgery alone may not be sufficient. Vaginal brachytherapy is frequently added for high-risk stage I cases as a preventative measure to reduce the chance of local recurrence. At this stage, systemic treatments like endometrial cancer chemotherapy drugs are generally not part of the picture, though that calculus shifts significantly at later stages.

Fertility-sparing consideration: For a very narrow group of patients with stage IA, grade 1 disease who haven’t yet completed childbearing, progestin therapy may be discussed as an alternative to immediate surgery. This option requires close monitoring and is only appropriate for carefully selected cases.

As cancer advances beyond the uterus itself, the treatment approach becomes more complex, which is exactly what Stage II involves.

Stage II: addressing spread to the cervical stroma

Stage II uterine cancer involves cancer that has moved into the connective tissue of the cervix, called the cervical stroma. While this is more advanced than what’s managed in endometrial cancer stage I treatment, it’s still considered localized disease, and the approach remains centered on achieving a surgical cure.

The defining difference at stage II is the type of surgery required. Rather than a standard total hysterectomy, which removes the uterus and cervix, surgeons typically perform a radical hysterectomy, which removes the uterus, cervix, and the surrounding parametrial tissue, along with the upper portion of the vagina. The goal is to achieve wide, clear margins and reduce the risk of leaving any cancer cells behind in adjacent structures.

Because the cancer has reached the cervix, radiation plays a central role in post-surgical care. Stage II treatment often involves radical hysterectomy followed by radiation to ensure no local recurrence. External Beam Radiation Therapy (EBRT) delivers targeted radiation to the pelvic region, addressing any microscopic disease that surgery may not have captured. Vaginal brachytherapy is sometimes added as well, depending on pathology findings.

Recovery from this combination of surgery and radiation can be demanding. Some patients undergoing stage II treatment find that pelvic floor physical therapy may help with recovery; ask your care team whether this approach could be beneficial for you. Pelvic floor physical therapy can help manage changes in bladder and bowel function, pelvic muscle tension, and the physical effects of pelvic radiation that can persist well after treatment ends. Asking your care team for a referral early in recovery is worth considering.

When cancer spreads further, to lymph nodes or beyond the pelvis, the treatment strategy shifts considerably, requiring a more systemic approach.

Stage III: a ‘sandwich method’ and systemic defense

Stage III uterine cancer, where spread reaches the lymph nodes, vagina, or outer uterine surface, calls for a coordinated multimodal strategy that goes well beyond surgery alone.

When the cancer has extended this far, a single treatment approach isn’t enough. That’s where the “sandwich method” comes in. The sandwich method sequences treatment as chemotherapy, followed by radiation, followed by more chemotherapy. Chemotherapy targets cancer cells that may have traveled beyond the pelvis, while radiation addresses the regional tumor site directly. Carboplatin and Paclitaxel (also known as Taxol) form the standard chemotherapy regimen for advanced uterine cancer, and this combination anchors both phases of the sandwich.

Managing side effects across this extended treatment course is one of the most challenging aspects of stage III care. Radiation for uterine cancer side effects, including pelvic discomfort, bowel changes, and vaginal dryness, overlap with chemotherapy-related effects like fatigue, nausea, and hair loss. Peripheral neuropathy, which is a tingling or numbness in the hands and feet, is caused by Paclitaxel and is particularly common. Some patients find it helpful to connect with others navigating similar pelvic radiation experiences through cancer support communities to understand what to expect day to day.

Common side effects:

Carboplatin

• Fatigue
• Nausea
• Low blood counts
• Kidney stress

Paclitaxel (Taxol)

• Peripheral neuropathy
• Hair loss
• Muscle aches
• Low blood counts

Stage IV and recurrent cancer: the shift to personalized medicine

Stage IV uterine cancer represents disease where spread has reached the bladder, bowel, or distant organs such as the lungs, and treatment goals shift from cure to long-term management and quality of life.

While the chemotherapy regimens used for stage III remain part of the picture here, stage IV care increasingly centers on your tumor’s genetic profile. Your genetic profile, including genetic markers of your cancer, is one of several factors your care team will consider when designing a personalized treatment plan for uterine cancer. Immunotherapy with pembrolizumab is now a standard option for patients whose tumors carry MSI-H or dMMR markers, either alongside chemotherapy or as a subsequent line of therapy.

For patients without MSI-H or dMMR status, targeted therapy offers another modern path. Lenvatinib, often combined with pembrolizumab, has shown meaningful results in stage IV uterine cancer patients without MSI-H or dMMR status.

Clinical trials provide access to emerging combinations and novel agents that standard protocols haven’t yet adopted. In advanced and recurrent uterine cancer, clinical trials are exploring emerging therapies that may offer additional options alongside or instead of standard chemotherapy. Ask your care team whether a clinical trial might be appropriate for your situation.

The bottom line: what you need to know

Uterine cancer treatment follows a clear logic: the further the disease has spread, the more tools your care team needs to deploy. Here’s what to carry forward from everything covered in this article:

• Stage drives the surgical foundation. A hysterectomy for uterine cancer is the cornerstone of treatment from Stage I through Stage III. Early-stage disease is often resolved with surgery alone, while higher stages layer in systemic chemotherapy and radiation on top of that surgical base.
• Genetic testing is now a clinical requirement. MSI-H/dMMR status determines whether immunotherapy, specifically pembrolizumab, belongs in Stage IV or recurrent uterine cancer treatment plans. Skipping biomarker testing means potentially missing your most effective option.
• Radiation is not one-size-fits-all. Brachytherapy targets the vaginal cuff locally, while external beam radiation (EBRT) addresses broader pelvic spread. Your pathology, not a standard protocol, determines which form, or which combination, is appropriate. Knowing the difference matters when preparing for combined treatment.
• Clinical trials are active treatment options. They’re worth evaluating at every stage.

Empowered patients who understand their genetic markers are better equipped to navigate advanced treatment options, and that understanding starts with asking the right questions.

Taking control: how to navigate your personalized path

Managing uterine cancer treatment means coordinating across multiple specialists, surgeons, radiation oncologists, and medical oncologists, each responsible for a different piece of your care. That complexity is real, and it’s a lot to hold together on your own.

Support is available to help you navigate this. When you understand what’s driving each recommendation, your stage, your biomarkers, your molecular profile, you’re better positioned to ask the right questions and advocate for yourself in every appointment.

Digital tools also matter beyond those conversations. Tracking your symptoms between visits, organizing your genetic test results, and keeping a clear record of what you’ve been prescribed all reduce the cognitive load that builds quickly after a diagnosis. Secure, centralized access to that information means nothing slips through the cracks when your care team changes or when you’re considering a second opinion.

Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.